Studies have shown that blocking CCL2/CCR2 interaction can inhibit the recruitment and activation of M2-TAM and significantly reduce the incidence of tumors: blocking CCL2 by crumb (CNTO88) can inhibit the growth of prostate cancer cells (111, 112); PF-04136309(CCR2 inhibitor) can act on CCR2+ monocytes, prevent the recruitment and migration of M2-TAM, and further enhance anti-tumor immunity (113). This evidence concerns the gene CCL2 and Familial prostate cancer.